Download PDF
Exp Clin Endocrinol Diabetes 2019; 127(S 01): S97-S101
DOI: 10.1055/a-1018-9228
German Diabetes Association: Clinical Practice Guidelines
© Georg Thieme Verlag KG Stuttgart · New York

Position Paper on Lipid Therapy in Patients with Diabetes Mellitus

A Joint Statement by the Commission on Lipometabolism and The Heart and Diabetes Working Group of the German Diabetes Society (DDG), The Diabetology and Metabolism Section of The German Society of Endocrinology (DGE), The Heart and Diabetes Working Group of the German Cardiology Society (DGK) and The Joint Heart - Hormones – Diabetes Working Group of the DGK, DGE and DDG
Klaus G. Parhofer
1   Medical Department IV-Grosshadern, University of Munich, Munich, Germany
,
Andreas L. Birkenfeld
2   Medical Clinic IV, University Hospital, Tübingen, Germany
3   Institute for Diabetes Research and Metabolic Diseases (IDM) of Helmholtz Zentrum München at the Tübingen University, German Centre for Diabetes Research, Germany
,
Wilhelm Krone
4   Polyclinic for Endocrinology, Diabetology and Preventive Medicine, University Hospital Cologne, Cologne, Germany
,
Michael Lehrke
5   Medical Clinic I - Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
,
Nikolaus Marx
5   Medical Clinic I - Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
,
Martin Merkel
6   Endocrinologikum Hamburg, Hamburg, Germany
,
Katharina S. Schütt
5   Medical Clinic I - Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
,
Andreas Zirlik
7   Clinic for Cardiology and Angiology I, University Heart Centre, Freiburg, Germany
,
Dirk Müller-Wieland
5   Medical Clinic I - Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2019 (online)

Also available at
   Permissions and Reprints

Introduction

Patients with diabetes mellitus generally have a significantly increased cardiovascular risk. For this reason, lipid therapy and a reduction in LDL cholesterol based on risk stratification are an integral part of diabetes therapy; the following position paper should therefore also be viewed as a topic-related supplement to the annually updated recommendation for the treatment of type 2 diabetes and should also be updated annually in future together with the DDGʼs practical recommendations.

The recently published guidelines and recommendations of the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), the American Association of Clinical Endocrinologists (AACE), the American Diabetes Association (ADA) and the American National Lipid Society (NLA) [1] [2] [3] [4] [5] form the basis for the information contained below.

This position paper is therefore to be understood as a short, current, clinically-oriented recommendation for action in patients with diabetes; for in-depth explanations on lipid metabolism and the use of lipid disorders, please refer to the literature provided.

 

  • References

  • 1 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardio- vascular risk. Eur Heart J 2019;
    CrossrefPubMedSearch in Google Scholar
  • 2 Jacobson TA, Ito MK, Maki KC. et al. National lipid association recommendations for patient-centered management of dyslipidemia: Part 1– full report. J Clin Lipidol 2015; 9: 129-169
    CrossrefPubMedSearch in Google Scholar
  • 3 Jacobson TA, Maki KC, Orringer CE. et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol 2015; 9: S1-S122 e1
    CrossrefPubMedSearch in Google Scholar
  • 4 Jellinger PS, Handelsman Y, Rosenblit PD. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease – Executive Summary. Complete Appendix to Guidelines available at: http://journals.aace.com Endocr Pract 2017; 23: 479-497
    CrossrefPubMedSearch in Google Scholar
  • 5 American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41 (Suppl. 1) S86-S104
    CrossrefPubMedSearch in Google Scholar
  • 6 Gregg EW, Li Y, Wang J. et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 2014; 370: 1514-1523
    CrossrefPubMedSearch in Google Scholar
  • 7 Yusuf S, Hawken S, Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Inter- heart study): Case-control study. Lancet 2004; 364: 937-952
    CrossrefPubMedSearch in Google Scholar
  • 8 Nordestgaard BG, Langsted A, Mora S. et al. Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points-A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37: 1944-1958
    CrossrefPubMedSearch in Google Scholar
  • 9 Sniderman AD, De Graaf J, Couture P. et al. Regulation of plasma LDL: The apoB paradigm. Clin Sci (Lond) 2010; 118: 333-339
    CrossrefPubMedSearch in Google Scholar
  • 10 Parhofer KG. The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int 2016; 113: 261-268
    PubMedSearch in Google Scholar
  • 11 Moriarty PM, Parhofer KG, Babirak SP. et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: The ODYSSEY ESCAPE trial. Eur Heart J 2016; 37: 3588-3595
    CrossrefPubMedSearch in Google Scholar
  • 12 Ewald N, Kloer HU. Treatment options for severe hypertriglyceridemia (SHTG): The role of apheresis. Clin Res Cardiol Suppl 2012; 7 (Suppl. 1) 31-35
    CrossrefPubMedSearch in Google Scholar